| Added by | standudu |
|---|---|
| Group name | EquipeCTCS |
| Item Type | Journal Article |
| Title | The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway |
| Creator | Laprevotte et al. |
| Author | Emilie Laprevotte |
| Author | Stéphanie Cochaud |
| Author | Stanislas du Manoir |
| Author | Marion Lapierre |
| Author | Cécile Dejou |
| Author | Marion Philippe |
| Author | Jérome Giustiniani |
| Author | Kathryn A. Frewer |
| Author | Andrew J. Sanders |
| Author | Wen G. Jiang |
| Author | Henri-Alexandre Michaud |
| Author | Pierre-Emmanuel Colombo |
| Author | Armand Bensussan |
| Author | Gilles Alberici |
| Author | Jérémy Bastid |
| Author | Jean-François Eliaou |
| Author | Nathalie Bonnefoy |
| Abstract | Interleukin 17B (IL-17B) is a pro-inflammatory cytokine that belongs to the IL-17 cytokines family and binds to IL-17 receptor B (IL-17RB). Here we found that high expression of IL-17B and IL-17RB is associated with poor prognosis in patients with breast cancer and that IL-17B expression upregulation is specifically associated with poorer survival in patients with basal-like breast cancer. We thus focused on IL-17B role in breast cancer by using luminal and triple negative (TN)/basal-like tumor cell lines. We found that IL-17B induces resistance to conventional chemotherapeutic agents. In vivo, IL-17B induced resistance to paclitaxel and treatment with an anti-IL-17RB neutralizing antibody completely restored breast tumor chemosensitivity, leading to tumor shrinkage. We next focused on the signaling pathways activated in human breast cancer cell lines upon incubation with IL-17B. We observed that IL-17B induces ERK1/2 pathway activation, leading to upregulation of anti-apoptotic proteins of the BCL-2 family. IL-17B-induced chemoresistance was completely abolished by incubation with PD98059, an inhibitor of the MAPK/ERK pathway, indicating that the ERK pathway plays a crucial role. Altogether our results emphasize the role of the IL-17B/IL-17RB signaling pathway in breast tumors and identify IL-17B and its receptor as attractive therapeutic targets for potentiating breast cancer chemotherapy. |
| Publication | Oncotarget |
| Volume | 8 |
| Issue | 69 |
| Pages | 113360-113372 |
| Date | Dec 26, 2017 |
| Journal Abbr | Oncotarget |
| Language | eng |
| DOI | 10.18632/oncotarget.23008 |
| ISSN | 1949-2553 |
| Library Catalog | PubMed |
| Extra | PMID: 29371916 PMCID: PMC5768333 |
| Tags | breast cancer, chemoresistance, interleukin-17, interleukin-17B, original |
| Date Added | 2018/11/14 - 15:24:24 |
| Date Modified | 2019/05/14 - 18:26:57 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
